<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539123</url>
  </required_header>
  <id_info>
    <org_study_id>0506000082</org_study_id>
    <secondary_id>R01DA014718-05A1</secondary_id>
    <nct_id>NCT00539123</nct_id>
  </id_info>
  <brief_title>Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia</brief_title>
  <official_title>Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial evaluating whether Behavioral Drug and HIV Risk Reduction&#xD;
      Counseling (BDRC), abstinence-contingent take-home buprenorphine (ACB), or the combination of&#xD;
      the two improve efficacy and cost-effectiveness of standard buprenorphine treatment for&#xD;
      opiate-dependent individuals in Malaysia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heroin and injection drug use (IDU) are highly prevalent and driving the HIV epidemic in&#xD;
      Malaysia and other countries in the region. In our original RCT, buprenorphine was superior&#xD;
      to naltrexone and placebo in treatment retention, weeks of consecutive abstinence and time to&#xD;
      heroin use. However, there is room for improvement, since only 50% of subjects assigned to&#xD;
      buprenorphine and counseling remained in treatment for 6 months; only 28% avoided relapse to&#xD;
      heroin; and treatment reduced drug- but not sex-related HIV risk behaviors. In actual&#xD;
      clinical practice in Malaysia and the U.S. buprenorphine treatment effectiveness may be even&#xD;
      less, because buprenorphine is provided with relatively minimal psychosocial services (often&#xD;
      brief physician management (PM) alone, without additional counseling), and without additional&#xD;
      behavioral interventions or contingency management. Hence, we propose a follow up study to&#xD;
      evaluate whether standard buprenorphine treatment (consisting of buprenorphine provision, PM,&#xD;
      and non-contingent provision of take-home doses of buprenorphine, NCB) is sufficient or&#xD;
      whether one or a combination of two behavioral treatments--behavioral drug and HIV risk&#xD;
      reduction counseling (BDRC) or abstinence-contingent take-home buprenorphine (ACB)-improve&#xD;
      its efficacy. BDRC utilizes short-term behavioral contracts to promote abstinence and reduce&#xD;
      drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants&#xD;
      available in medical settings in Malaysia. ACB, a low cost and feasible alternative to&#xD;
      non-contingent take-home buprenorphine (NCB), retains many of its advantages--abstinent&#xD;
      patients manage their medication supplies outside of the clinic--but ACB also provides&#xD;
      positive incentives for abstinence and directly observed buprenorphine for those with&#xD;
      continuing heroin use. In the proposed 2X2 study, heroin dependent patients (N=240) will be&#xD;
      inducted onto buprenorphine (weeks 1-2) and then randomized to PM with NCB, PM with ACB, PM&#xD;
      with BDRC and NCB, or PM with BDRC and ACB (weeks 3-26). Primary outcome measures include&#xD;
      reductions in heroin use (percent days abstinent, proportion of opiate-negative urine tests)&#xD;
      and reductions in drug- and sex-related HIV risk behaviors. Data analyses will focus on the&#xD;
      intention-to treat sample. The study results will inform practice guidelines and policies&#xD;
      regarding buprenorphine treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2x2 factorial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reductions in heroin use</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>reductions in drug- and sex-related HIV risk</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>retention</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reductions in other illicit drug use</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in functional status</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>NCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Physician Management (PM) and non-contingent provision of take-home doses of buprenorphine-naloxone (NCB).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Physician Management (PM) and abstinence-contingent provision of take-home doses of buprenorphine-naloxone (ACB).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>behavioral drug and HIV risk reduction counseling (BDRC)</intervention_name>
    <description>BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.</description>
    <arm_group_label>NCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>abstinence-contingent buprenorphine (ACB)</intervention_name>
    <description>Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.</description>
    <arm_group_label>ACB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  opioid dependence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current dependence on alcohol, benzodiazepines or sedatives current suicide or&#xD;
             homicide risk current psychotic disorder or major depression inability to understand&#xD;
             protocol or assessment questions life threatening or unstable medical problems more&#xD;
             than 3x normal liver enzymes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S. Schottenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmud Mazlan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Substance Abuse Research Center, Muar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Substance Abuse Research Center</name>
      <address>
        <city>Muar</city>
        <state>Johor</state>
        <zip>84000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>buprenorphine</keyword>
  <keyword>drug counseling</keyword>
  <keyword>HIV risk reduction counseling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

